Erratum: Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII Promotes Self-renewal and Tumor Progression of Glioma Stem Cells (PLoS Biology (2015) 13:5 (e1002152) DOI: 10.1371/journal.pbio.1002152);Pigment Epithelium-Derived Factor (PEDF) Expression Induced by EGFRvIII Promotes Self-renewal and Tumor Progression of Glioma Stem Cells

PLoS Biology

Volumn 13, Issue 5, 2015, Pages

  Yin, Jinlong ^a   Park, Gunwoo ^a   Kim, Tae Hoon ^a   Hong, Jun Hee ^a   Kim, Youn Jae ^a   Jin, Xiong ^b   Kang, Sangjo ^a   Jung, Ji Eun ^a,b   Kim, Jeong Yub ^c,d   Yun, Hyeongsun ^a   Lee, Jeong Eun ^a   Kim, Minkyung ^a   Chung, Junho ^d   Kim, Hyunggee ^b   Nakano, Ichiro ^e,f   Gwak, Ho Shin ^a   Yoo, Heon ^a   Yoo, Byong Chul ^a   Kim, Jong Heon ^a   Hur, Eun Mi ^g,h   Lee, Jeongwu ⁱ   Lee, Seung Hoon ^a   Park, Myung Jin ^c   Park, Jong Bae ^a   more..

^a National Cancer Center   (South Korea)

^b Korea University   (South Korea)

^c Division of Radiation Cancer Research   (South Korea)

^d Seoul National University College of Medicine   (South Korea)

^e OHIO STATE UNIVERSITY   (United States)

^f OHIO STATE UNIVERSITY   (United States)

^g Korea Institute of Science and Technology   (South Korea)

^h University of Science and Technology (UST)   (South Korea)

ⁱ LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 8; NOTCH1 RECEPTOR; PIGMENT EPITHELIUM DERIVED FACTOR; STAT3 PROTEIN; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG; EPIDERMAL GROWTH FACTOR RECEPTOR VIII; EYE PROTEIN; NERVE GROWTH FACTOR; NOTCH RECEPTOR; PIGMENT EPITHELIUM-DERIVED FACTOR; SERINE PROTEINASE INHIBITOR; SOX2 PROTEIN, HUMAN; STAT3 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASTROCYTOMA; CANCER SURVIVAL; CELL INFILTRATION; CELL RENEWAL; CONTROLLED STUDY; CORPUS CALLOSUM; FEMALE; GLIOMA STEM CELL; HUMAN; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PROTEIN CLEAVAGE; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; SIGNAL TRANSDUCTION; SURVIVAL RATE; TUMOR GROWTH; ANIMAL; AUTOCRINE EFFECT; BAGG ALBINO MOUSE; CANCER STEM CELL; DISEASE COURSE; EXPERIMENTAL NEOPLASM; GLIOMA; HEK293 CELL LINE; METABOLISM; MORTALITY; NUDE MOUSE;

MUS;

ANIMALS; AUTOCRINE COMMUNICATION; DISEASE PROGRESSION; EYE PROTEINS; FEMALE; GLIOMA; HEK293 CELLS; HUMANS; MICE, INBRED BALB C; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; NEOPLASTIC STEM CELLS; NERVE GROWTH FACTORS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECEPTORS, NOTCH; SERPINS; SOXB1 TRANSCRIPTION FACTORS; STAT3 TRANSCRIPTION FACTOR;

EID: 84930671246     PISSN: 15449173     EISSN: 15457885     Source Type: Journal    
DOI: 10.1371/journal.pbio.1002367     Document Type: Erratum

References (71)

1. Wen PY, Kesari S, Malignant gliomas in adults. N Engl J Med. 2008; 359: 492–507. doi: 10.1056/NEJMra0708126 18669428
2. Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009; 10: 459–466. doi: 10.1016/S1470-2045(09)70025-7 19269895
3. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, et al. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev. 2007; 21: 2683–2710. 17974913
4. Lefranc F, Brotchi J, Kiss R, Possible future issues in the treatment of glioblastomas: special emphasis on cell migration and the resistance of migrating glioblastoma cells to apoptosis. J Clin Oncol. 2005; 23: 2411–2422. 15800333
5. Jin X, Kim SH, Jeon HM, Beck S, Sohn YW, et al. Interferon regulatory factor 7 regulates glioma stem cells via interleukin-6 and Notch signalling. Brain. 2012; 135: 1055–1069. doi: 10.1093/brain/aws028 22434214
6. Takebe N, Harris PJ, Warren RQ, Ivy SP, Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol. 2011; 8: 97–106. doi: 10.1038/nrclinonc.2010.196 21151206
7. Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, et al. Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell. 2006; 9: 391–403. 16697959
8. Louis DN, Molecular pathology of malignant gliomas. Annu Rev Pathol. 2006; 1: 97–117. 18039109
9. Pollard SM, Yoshikawa K, Clarke ID, Danovi D, Stricker S, et al. Glioma stem cell lines expanded in adherent culture have tumor-specific phenotypes and are suitable for chemical and genetic screens. Cell Stem Cell. 2009; 4: 568–580. doi: 10.1016/j.stem.2009.03.014 19497285
10. Sadahiro H, Yoshikawa K, Ideguchi M, Kajiwara K, Ishii A, et al. Pathological features of highly invasive glioma stem cells in a mouse xenograft model. Brain Tumor Pathol. 2014; 31: 77–84. doi: 10.1007/s10014-013-0149-x 23670138
11. Gage FH, Mammalian neural stem cells. Science. 2000; 287: 1433–1438. 10688783.
12. Hjelmeland AB, Wu Q, Wickman S, Eyler C, Heddleston J, et al. Targeting A20 decreases glioma stem cell survival and tumor growth. PLoS Biol. 2010; 8: e1000319. doi: 10.1371/journal.pbio.1000319 20186265
13. Yin J, Park G, Lee JE, Park JY, Kim TH, et al. CPEB1 modulates differentiation of glioma stem cells via downregulation of HES1 and SIRT1 expression. Oncotarget. 2014; 5: 6756–6769. 25216517
14. Zhang QB, Ji XY, Huang Q, Dong J, Zhu YD, et al. Differentiation profile of brain tumor stem cells: a comparative study with neural stem cells. 2006; 16: 909–915.
15. Lim DA, Tramontin AD, Trevejo JM, Herrera DG, Garcia-Verdugo JM, et al. Noggin antagonizes BMP signaling to create a niche for adult neurogenesis. Neuron. 2000; 28: 713–726. 11163261
16. Panchision DM, McKay RD, The control of neural stem cells by morphogenic signals. Curr Opin Genet Dev. 2002; 12: 478–487. 12100896
17. Piccirillo SG, Reynolds BA, Zanetti N, Lamorte G, Binda E, et al. Bone morphogenetic proteins inhibit the tumorigenic potential of human brain tumour-initiating cells. Nature. 2006; 444: 761–765. 17151667
18. Nagane M, Levitzki A, Gazit A, Cavenee WK, Huang HJ, Drug resistance of human glioblastoma cells conferred by a tumor-specific mutant epidermal growth factor receptor through modulation of Bcl-XL and caspase-3-like proteases. Proc Natl Acad Sci U S A. 1998; 95: 5724–5729. 9576951
19. Nagane M, Narita Y, Mishima K, Levitzki A, Burgess AW, et al. Human glioblastoma xenografts overexpressing a tumor-specific mutant epidermal growth factor receptor sensitized to cisplatin by the AG1478 tyrosine kinase inhibitor. J Neurosurg. 2001; 95: 472–479. 11565870
20. Gan HK, Kaye AH, Luwor RB, The EGFRvIII variant in glioblastoma multiforme. J Clin Neurosci. 2009; 16: 748–754. doi: 10.1016/j.jocn.2008.12.005 19324552
21. Li L, Dutra A, Pak E, Labrie JE, Gerstein RM, et al. EGFRvIII expression and PTEN loss synergistically induce chromosomal instability and glial tumors. Neuro Oncol. 2009;11: 9–21. doi: 10.1215/15228517-2008-081 18812521
22. Li B, Yuan M, Kim IA, Chang CM, Bernhard EJ, et al. Mutant epidermal growth factor receptor displays increased signaling through the phosphatidylinositol-3 kinase/AKT pathway and promotes radioresistance in cells of astrocytic origin. Oncogene. 2004; 23: 4594–4602. 15077177
23. Narita Y, Nagane M, Mishima K, Huang HJ, Furnari FB, et al. Mutant epidermal growth factor receptor signaling down-regulates p27 through activation of the phosphatidylinositol 3-kinase/Akt pathway in glioblastomas. Cancer Res. 2002; 62: 6764–6769. 12438278
24. Zhang Y, Su H, Rahimi M, Tochihara R, Tang C, EGFRvIII-induced estrogen-independence, tamoxifen-resistance phenotype correlates with PgR expression and modulation of apoptotic molecules in breast cancer. Int J Cancer. 2009; 125: 2021–2028. doi: 10.1002/ijc.24540 19588487
25. Emlet DR, Gupta P, Holgado-Madruga M, Del Vecchio CA, Mitra SS, et al. Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. Cancer Res. 2014; 74: 1238–1249. doi: 10.1158/0008-5472.CAN-13-1407 24366881
26. Hamerlik P, Lathia JD, Rasmussen R, Wu Q, Bartkova J, et al. Autocrine VEGF-VEGFR2-Neuropilin-1 signaling promotes glioma stem-like cell viability and tumor growth. J Exp Med. 2012; 209: 507–520. doi: 10.1084/jem.20111424 22393126
27. Ikushima H, Todo T, Ino Y, Takahashi M, Miyazawa K, et al. Autocrine TGF-beta signaling maintains tumorigenicity of glioma-initiating cells through Sry-related HMG-box factors. Cell Stem Cell. 2009; 5: 504–514. doi: 10.1016/j.stem.2009.08.018 19896441
28. Yan K, Wu Q, Yan DH, Lee CH, Rahim N, et al. Glioma cancer stem cells secrete Gremlin1 to promote their maintenance within the tumor hierarchy. Genes Dev. 2014; 28: 1085–1100. doi: 10.1101/gad.235515.113 24788093
29. Scheel C, Eaton EN, Li SH, Chaffer CL, Reinhardt F, et al. Paracrine and autocrine signals induce and maintain mesenchymal and stem cell states in the breast. Cell. 2011; 145: 926–940. doi: 10.1016/j.cell.2011.04.029 21663795
30. Andreu-Agullo C, Morante-Redolat JM, Delgado AC, Farinas I, Vascular niche factor PEDF modulates Notch-dependent stemness in the adult subependymal zone. Nat Neurosci. 2009; 12: 1514–1523. doi: 10.1038/nn.2437 19898467
31. Fan QW, Cheng CK, Gustafson WC, Charron E, Zipper P, et al. EGFR phosphorylates tumor-derived EGFRvIII driving STAT3/5 and progression in glioblastoma. Cancer Cell. 2013; 24: 438–449. doi: 10.1016/j.ccr.2013.09.004 24135280
32. de la Iglesia N, Konopka G, Puram SV, Chan JA, Bachoo RM, et al. Identification of a PTEN-regulated STAT3 brain tumor suppressor pathway. Genes Dev. 2008; 22: 449–462. doi: 10.1101/gad.1606508 18258752
33. Dawson DW, Volpert OV, Gillis P, Crawford SE, Xu H, et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science. 1999; 285: 245–248. 10398599
34. Ehm O, Goritz C, Covic M, Schaffner I, Schwarz TJ, et al. RBPJkappa-dependent signaling is essential for long-term maintenance of neural stem cells in the adult hippocampus. J Neurosci. 2010; 30: 13794–13807. doi: 10.1523/JNEUROSCI.1567-10.2010 20943920
35. Tyagi M, Karn J, CBF-1 promotes transcriptional silencing during the establishment of HIV-1 latency. EMBO J. 2007; 26: 4985–4995. 18007589
36. Bernard A, Gao-Li J, Franco CA, Bouceba T, Huet A, et al. Laminin receptor involvement in the anti-angiogenic activity of pigment epithelium-derived factor. J Biol Chem. 2009; 284: 10480–10490. doi: 10.1074/jbc.M809259200 19224861
37. Park K, Lee K, Zhang B, Zhou T, He X, et al. Identification of a novel inhibitor of the canonical Wnt pathway. Mol Cell Biol. 2011; 31: 3038–3051. doi: 10.1128/MCB.01211-10 21576363
38. Cheng G, Zhong M, Kawaguchi R, Kassai M, Al-Ubaidi M, et al. Identification of PLXDC1 and PLXDC2 as the transmembrane receptors for the multifunctional factor PEDF. Elife. 2014; 3: e05401. doi: 10.7554/eLife.05401 25535841
39. Cheung HC, Hai T, Zhu W, Baggerly KA, Tsavachidis S, et al. Splicing factors PTBP1 and PTBP2 promote proliferation and migration of glioma cell lines. Brain. 2009; 132: 2277–2288. doi: 10.1093/brain/awp153 19506066
40. Soeda A, Inagaki A, Oka N, Ikegame Y, Aoki H, et al. Epidermal growth factor plays a crucial role in mitogenic regulation of human brain tumor stem cells. J Biol Chem. 2008; 283: 10958–10966. doi: 10.1074/jbc.M704205200 18292095
41. Humphrey PA, Wong AJ, Vogelstein B, Zalutsky MR, Fuller GN, et al. Anti-synthetic peptide antibody reacting at the fusion junction of deletion-mutant epidermal growth factor receptors in human glioblastoma. Proc Natl Acad Sci U S A. 1990; 87: 4207–4211. 1693434
42. Wong AJ, Ruppert JM, Bigner SH, Grzeschik CH, Humphrey PA, et al. Structural alterations of the epidermal growth factor receptor gene in human gliomas. Proc Natl Acad Sci U S A. 1992; 89: 2965–2969. 1557402
43. Gan HK, Cvrljevic AN, Johns TG, The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered. FEBS J. 2013; 280: 5350–5370. doi: 10.1111/febs.12393 23777544
44. Inda MM, Bonavia R, Mukasa A, Narita Y, Sah DW, et al. Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev. 2010; 24: 1731–1745. doi: 10.1101/gad.1890510 20713517
45. Nishikawa R, Sugiyama T, Narita Y, Furnari F, Cavenee WK, et al. Immunohistochemical analysis of the mutant epidermal growth factor, deltaEGFR, in glioblastoma. Brain Tumor Pathol. 2004; 21: 53–56. 15700833
46. Liu XJ, Wu WT, Wu WH, Yin F, Ma SH, et al. A minority subpopulation of CD133(+) /EGFRvIII(+) /EGFR(-) cells acquires stemness and contributes to gefitinib resistance. CNS Neurosci Ther. 2013; 19: 494–502. doi: 10.1111/cns.12092 23575351
47. Sampson JH, Heimberger AB, Archer GE, Aldape KD, Friedman AH, et al. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma. J Clin Oncol. 2013; 28: 4722–4729.
48. Calabrese C, Poppleton H, Kocak M, Hogg TL, Fuller C, et al. A perivascular niche for brain tumor stem cells. Cancer Cell. 2007; 11: 69–82. 17222791
49. Li Z, Bao S, Wu Q, Wang H, Eyler C, et al. Hypoxia-inducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell. 2009: 15: 501–513. doi: 10.1016/j.ccr.2009.03.018 19477429
50. Seidel S, Garvalov BK, Wirta V, von Stechow L, Schanzer A, et al. A hypoxic niche regulates glioblastoma stem cells through hypoxia inducible factor 2 alpha. Brain. 2010; 133: 983–995. doi: 10.1093/brain/awq042 20375133
51. Morrison SJ, Spradling AC, Stem cells and niches: mechanisms that promote stem cell maintenance throughout life. Cell. 2008; 132: 598–611. doi: 10.1016/j.cell.2008.01.038 18295578
52. Nystul TG, Spradling AC, Breaking out of the mold: diversity within adult stem cells and their niches. Curr Opin Genet Dev. 2006; 16: 463–468. 16919446
53. Watt FM, Hogan BL, Out of Eden: stem cells and their niches. Science. 2000; 287: 1427–1430. 10688781
54. Doetsch F, A niche for adult neural stem cells. Curr Opin Genet Dev. 2003; 13: 543–550. 14550422
55. Seki T, Hippocampal adult neurogenesis occurs in a microenvironment provided by PSA-NCAM-expressing immature neurons. J Neurosci Res. 2002; 69: 772–783. 12205671
56. Menn B, Garcia-Verdugo JM, Yaschine C, Gonzalez-Perez O, Rowitch D, et al. Origin of oligodendrocytes in the subventricular zone of the adult brain. J Neurosci. 2006; 26: 7907–7918. 16870736
57. Cayre M, Canoll P, Goldman JE, Cell migration in the normal and pathological postnatal mammalian brain. Prog Neurobiol. 2009; 88: 41–63. doi: 10.1016/j.pneurobio.2009.02.001 19428961
58. Steele FR, Chader GJ, Johnson LV, Tombran-Tink J, Pigment epithelium-derived factor: neurotrophic activity and identification as a member of the serine protease inhibitor gene family. Proc Natl Acad Sci U S A. 1993; 90: 1526–1530. 8434014
59. Tombran-Tink J, Chader GG, Johnson LV, PEDF: a pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res. 1991; 53: 411–414. 1936177
60. Tsao YP, Ho TC, Chen SL, Cheng HC, Pigment epithelium-derived factor inhibits oxidative stress-induced cell death by activation of extracellular signal-regulated kinases in cultured retinal pigment epithelial cells. Life Sci. 2006; 79: 545–550. 16504212
61. Takanohashi A, Yabe T, Schwartz JP, Pigment epithelium-derived factor induces the production of chemokines by rat microglia. Glia. 2005; 51: 266–278. 15816038
62. Becerra SP, Notario V, The effects of PEDF on cancer biology: mechanisms of action and therapeutic potential. Nat Rev Cancer. 2013; 13: 258–271. doi: 10.1038/nrc3484 23486238
63. Gaiano N, Fishell G, The role of notch in promoting glial and neural stem cell fates. Annu Rev Neurosci. 2002; 25: 471–490. 12052917
64. Fan X, Matsui W, Khaki L, Stearns D, Chun J, et al. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res. 2006; 66: 7445–7452. 16885340
65. Zhang XP, Zheng G, Zou L, Liu HL, Hou LH, et al. Notch activation promotes cell proliferation and the formation of neural stem cell-like colonies in human glioma cells. Mol Cell Biochem. 2008; 307: 101–108. 17849174
66. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, et al. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem Cells. 2010; 28: 5–16. doi: 10.1002/stem.254 19904829
67. Wang J, Wakeman TP, Lathia JD, Hjelmeland AB, Wang XF, et al. Notch promotes radioresistance of glioma stem cells. Stem Cells. 2010; 28: 17–28. doi: 10.1002/stem.261 19921751
68. Suva ML, Rheinbay E, Gillespie SM, Patel AP, Wakimoto H, et al. Reconstructing and reprogramming the tumor-propagating potential of glioblastoma stem-like cells. Cell. 2014; 157: 580–594. doi: 10.1016/j.cell.2014.02.030 24726434
69. Zhu H, Acquaviva J, Ramachandran P, Boskovitz A, Woolfenden S, et al. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc Natl Acad Sci U S A. 2009; 106: 2712–2716. doi: 10.1073/pnas.0813314106 19196966
70. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, et al. Identification of human brain tumour initiating cells. Nature. 2004; 432: 396–401. 15549107
71. Yamoutpour F, Bodempudi V, Park SE, Pan W, Mauzy MJ, et al. Gene silencing for epidermal growth factor receptor variant III induces cell-specific cytotoxicity. Mol Cancer Ther. 2008; 7: 3586–3597. doi: 10.1158/1535-7163.MCT-08-0653 19001441